INAB, US45674E2081

IN8bio stock has November 5, 2026 earnings date

Published on 10/15/2026 at 22:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IN8bio lost USD 4.78 million in the second quarter of 2026. IN8bio stock costs EUR 1.06 on October 15, 2026 at 10:19 p.m. CEST.

Scheduled results and valuation

MarketBeat estimates that IN8bio will report third-quarter results on November 5, 2026.
IN8bio posted a USD 4.78 million net loss in the second quarter of 2026.
IN8bio stock costs EUR 1.06 at Lang & Schwarz on October 15, 2026 at 10:19 p.m. CEST.
IN8bio had a negative P/E ratio of -0.63 on October 15, 2026.

INAB, US45674E2081, Illustration mit AI erstellt.

IN8bio (ISIN US45674E2081) is estimated to report its third-quarter 2026 results on November 5, 2026, before the market opens, according to MarketBeat. The date is the next scheduled event in the company calendar. IN8bio stock was at EUR 1.06 at Lang & Schwarz on October 15, 2026 at 10:19 p.m. CEST.

Second-quarter loss reached USD 4.78 million

IN8bio reported a GAAP net loss of USD 4.78 million for the second quarter of 2026, compared with a USD 5.09 million loss in the second quarter of 2025. The result represents a narrower loss of USD 0.31 million year over year. Markets Insider reported the figures and said the company remained focused on its clinical-stage development programs.

The company held USD 17.96 million in cash at June 30, 2026, while operating cash flow was negative USD 3.75 million in the second quarter. That cash position and quarterly cash use frame the importance of the November reporting date for investors tracking funding needs.

EUR 1.06 marks the latest quote

The Lang & Schwarz quote stood at EUR 1.06 on October 15, 2026 at 10:19 p.m. CEST. The latest Nasdaq quote was USD 1.19 on October 15, 2026 at 4:00 p.m. ET, versus a USD 1.20 previous close. IN8bio is developing gamma-delta T-cell therapies for cancer and autoimmune diseases, according to the company investor-relations page.

Valuation and next reporting date

IN8bio had a market capitalization of USD 11.7 million and a negative P/E ratio of -0.63 on October 15, 2026. The company paid no dividend yield in the quoted period. The estimated November 5, 2026 results date gives the market a defined calendar point for the next operating update.

Comparison with peers

INAB (Nasdaq, USD): P/E -0.63, market capitalization USD 11.7 million.

Fate Therapeutics (Nasdaq, USD): minus 0.52 percent, P/E -1.83, market capitalization USD 224.4 million.

Caribou Biosciences (Nasdaq, USD): unchanged, P/E -0.43, market capitalization USD 49.8 million.

Trading perspective

IN8bio combines a small market value with continued clinical development spending. The second-quarter loss was lower than a year earlier, but cash usage remained negative, making the next results release the clearest scheduled checkpoint.

The latest euro quote was EUR 1.06 at Lang & Schwarz on October 15, 2026 at 10:19 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of IN8bio stock.